Omeros (OMER) Insider Demopulos Peter Md Buys 15,000 Shares

Inside the Cluster of Omeros Corporation Insider Buys

Omeros Corporation (NasdaqGM: OMER) saw a coordinated wave of insider activity on June 18, 2026, when multiple executives and board members each acquired 15,000 shares. Among them, Peter Demopulos stepped in to pick up 15,000 shares. This group transaction brought a shared wave of fresh equity purchases into the biopharmaceutical firm on a single day.

Group Purchases Across Leadership

The mid-June purchasing wave involved several key figures at the Seattle-based biotech company. Thomas Cable, Arnold Hanish, Thomas Bumol, Rajiv Shah, Diana Perkinson, and Hood Leroy MD PhD each purchased 15,000 shares on June 18, 2026. These coordinated acquisitions point to a broad show of internal engagement across the leadership team as the company moves forward with its clinical pipeline.

Stock Performance and Valuation

Shares of Omeros Corporation change hands on the NasdaqGM, sitting below their 52-week peak of $21.24 while well above the floor of $6.24. The stock trades with a price-to-earnings ratio of 15.40 and a forward price-to-earnings ratio of 15.28. The company has a beta of 2.57, meaning the stock tends to move more than the broader market, and a 50-day moving average resting at $18.23.

Analysts Set New Price Targets

Wall Street firms keep a positive outlook on the drug developer. On June 26, 2026, HC Wainwright & Co. maintained its buy rating while adjusting its price target to $33.00. Later in the summer, on September 22, 2026, Cantor Fitzgerald upgraded the stock to an overweight rating. Cantor Fitzgerald returned on October 14, 2026, to reiterate its overweight rating with a $22.00 price target. The stock holds a consensus buy recommendation from analysts, with a mean price target of $27.50.

Biotechnology Pipeline and Focus

Omeros Corporation focuses on discovering, developing, and commercializing small-molecule and protein therapeutics, along with orphan indications for immunologic diseases. Its lead product candidate, narsoplimab, targets hematopoietic stem-cell transplant-associated thrombotic microangiopathy and has been evaluated in clinical trials for COVID-19-related respiratory distress. The firm also develops compounds targeting lectin pathway disorders and various central nervous system conditions.

Looking Ahead to Earnings

Market participants tracking Omeros Corporation can look toward the company's next scheduled financial report on November 12, 2026, for further details on its clinical progress and revenue streams. The recent insider purchases offer a look at how leadership positions itself ahead of those upcoming disclosures.